Chat with us, powered by LiveChat
EN
ZH

Discover OncoGenerix: A Global Pharma Investment Opportunity

For qualified investors, OncoGenerix is now opening the door to their limited, early-stage investment offering within the injectable pharmaceutical industry.

Invest

Documents

Teaser

Two-pager deal summary

Download PDF

Executive Summary

Deal summary in 20 pages

Download PDF

Offering Structure

Description of the deal details

Download PDF

Sponsor Info

Team behind this offering

alphacapital.io

Location

Production Plant
Corporate Office
OncoGenerix Production Plant 157000, No.7, Dongxu Road, Hailin, Mudanjiang City, Heilongjiang Province People’s Republic of China
State-of-the-art manufacturing facility offers technical transfer, process development, process scale up, equipment and process validation, formulation, filling, lyophilization, inspection, integrity testing, labeling and packaging.
Current Production Area
19,662 m2
Future Expansion Space
15,543 m2
Total Site Area
39,870 m2
OncoGenerix Corporate Office USA OncoGenerix USA, Inc. 4455 Morena Blvd., Ste. 214 San Diego, CA 92117
OncoGenerix USA is the distributor of the products and services provided by the state-of-the-art sterile injectable facility located in Mudanjiang, China. OncoGenerix USA is responsible for:
  • Business Management
  • Contracts Approval and Execution
  • Business Development
  • Financial Management
Location 3
State-of-the-art manufacturing facility offers technical transfer, process development, process scale up, equipment and process validation, formulation, filling, lyophilization, inspection, integrity testing, labeling and packaging.
Current Production Area
19,662 m2
Future Expansion Space
15,543 m2
Total Site Area
39,870 m2

About OncoGenerix

Project Overview

As a global leader and provider for the next generation of compliant and high-quality manufacturing services for injectable products, OncoGenerix offers extensive experience in supplying high-quality injectable drug product sterile manufacturing services. Company services represent the entire pharma cycle, from early-stage drug development to global commercial supply.

Meet our

Strategic Partners

Shanghai Pharmaceuticals Holding Co. Ltd. is Largest holding company in China engaging in Pharmaceutical, Distribution and Supply Chain Solutions, Pharmaceutical Retail Operations

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions.

NYSC:SCR R&D — driven pharmaceutical company. It has been ranked amongst the top 100 pharmaceutical companies in China

Oasmia Pharmaceutical AB develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology

Pharma Resources (Germany) GmbH operates as a contract research organization that offers research, development, and manufacturing of small molecules.

Beloteca, Inc. is focused on the development of pharmaceutical products with an emphasis on sterile pharmaceutical products

Brick42 is a group of talented international business developers focused on guiding early stage and disruptive technologies into the market

Token

Offer Structure

Offered for sale is 100% of SPV, which, through intermediaries, possesses ownership of 10% in OncoGenerix production facility.
For Sale 10% of OG factory
Class A Shares 140
Price Per Share (A) $100,000.00
Class B Shares 1,500
Price Per Share (B) $20,000.00
Total Valuation $44,000,000
Your browser does not support SVG
OncoGenerix

Timeline

The timeline presents to you a transparent overview of the phases of OncoGenerix factory development and important milestones.

Stage 1

Throughout 2020, the Company will launch and sustain commercial production of (Product 1) for use by EU customers.

Concurrently, the Company is now engaged in Technical Transfer and Product Approval activities for (Product 5), (Product 6) and (Product 7).

Towards the end of the year, the Company will begin engaging in the Technical Transfer process for (Product 3) and (Product 8).

No material revenues from commercial production are to be expected during 2020.

In progress
2020

Stage 1 - description

Throughout 2020, the Company will launch and sustain commercial production of (Product 1) for use by EU customers.

Concurrently, the Company is now engaged in Technical Transfer and Product Approval activities for (Product 5), (Product 6) and (Product 7).

Towards the end of the year, the Company will begin engaging in the Technical Transfer process for (Product 3) and (Product 8).

No material revenues from commercial production are to be expected during 2020.

Stage 2

Throughout 2021, the Company expects commercialization of (Product 1) for the China market and (Product 6) for the EU market. Additionally, OncoGenerix will continue to scale the commercial production of (Product 1) for the EU market, which started in 2020.

During this coming year, OncoGenerix have forecasted for the Company to commence with the Technical Transfer processes for (Product 4) and (Product 9).

Concurrently during this year, OncoGenerix will be engaged in pre-commercialization activities for (Product 3), (Product 2), (Product 5), (Product 7), (Product 8) and (Product 9).

Upcoming
2021

Stage 2 - description

Throughout 2021, the Company expects commercialization of (Product 1) for the China market and (Product 6) for the EU market. Additionally, OncoGenerix will continue to scale the commercial production of (Product 1) for the EU market, which started in 2020.

During this coming year, OncoGenerix have forecasted for the Company to commence with the Technical Transfer processes for (Product 4) and (Product 9).

Concurrently during this year, OncoGenerix will be engaged in pre-commercialization activities for (Product 3), (Product 2), (Product 5), (Product 7), (Product 8) and (Product 9).

Stage 3

Throughout 2022, the Company expects the commercialization of (Product 2) for use in EU and China, (Product 3) for use in EU, China and US, (Product 8) for use in China, (Product 7) for use in EU and US, (Product 8) for use in EU, China, and the US.

Additional Technical Transfer projects are not currently forecasted for this year, under the current plan. However, the new pipeline can be added depending on capacity development and growth.

During this year, OncoGenerix will be engaged in pre-commercialization activities for (Product 4), (Product 5), (Product 7) as it relates to the China market only, and (Product 9).

Upcoming
2022

Stage 3 - description

Throughout 2022, the Company expects the commercialization of (Product 2) for use in EU and China, (Product 3) for use in EU, China and US, (Product 8) for use in China, (Product 7) for use in EU and US, (Product 8) for use in EU, China, and the US.

Additional Technical Transfer projects are not currently forecasted for this year, under the current plan. However, the new pipeline can be added depending on capacity development and growth.

During this year, OncoGenerix will be engaged in pre-commercialization activities for (Product 4), (Product 5), (Product 7) as it relates to the China market only, and (Product 9).

Stage 4

During 2023, the Company expects commercialization of (Product 4) for both the EU and US markets and (Product 9) for EU and US markets.

OncoGenerix management does not expect new Technical Transfer projects for this year, under the current plan. However, a new pipeline can be added depending on production capacity and future company growth.

Upcoming
2023

Stage 4 - description

During 2023, the Company expects commercialization of (Product 4) for both the EU and US markets and (Product 9) for EU and US markets.

OncoGenerix management does not expect new Technical Transfer projects for this year, under the current plan. However, a new pipeline can be added depending on production capacity and future company growth.

Stage 5

During OncoGenerix growth period, witnessing the pipeline build with new alliances and offerings, the Ccompany’s business strategy remained focused on a production portfolio with forecastable expansion. Going forward from 2024 and beyond is all about operating at an acceptable level of production and then executing the projects which OncoGenerix had activated in the previous years.

Upcoming
2024

Stage 5 - description

During OncoGenerix growth period, witnessing the pipeline build with new alliances and offerings, the Ccompany’s business strategy remained focused on a production portfolio with forecastable expansion. Going forward from 2024 and beyond is all about operating at an acceptable level of production and then executing the projects which OncoGenerix had activated in the previous years.

Meet our

Executive Leadership

The executives at OncoGenerix are proven industry leaders. Their wide array of know-how, skills, and insights spans across many business disciplines including: pharmaceuticals, healthcare, finance, law, and technology

Corporate Leadership
Facility Management
Oleksandr Zabudkin
CEO
Eric Palacios
Director of Facilities
Haixing Zheng
Director of Non-GMP Local External Affairs
Yanchao Liang
HR Manager
Yu Liu
Legal Counsel
Yingqi Zhu
Sales Manager
Weilin Ji
CFO
Ramana Reddy Muchumari
Director of Quality & RA
Li Chen
Quality Management
Jian Kang
Head of Human Resources
Bill Allan
Engineering Manager
Jin Wang
Deputy Director of Quality & RA
Abrar Jagirdar
Production Quality Control
Long Zhao
Engineer
Thomas Paul
Quality Control Manager
We always look forward to answering your questions

Contact us

Begin your new investment opportunity today with OncoGenerix!

contact us
Your browser does not support SVG Your browser does not support SVG Your browser does not support SVG
We always look forward to answering your questions

Contact us

Begin your new investment opportunity today with OncoGenerix!

Request for Private Deal

We are open to discuss special terms with investors looking to place over $250,000